Skip to main content
Top
Published in: Journal of Gastroenterology 12/2015

01-12-2015 | Original Article—Alimentary Tract

Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study

Authors: Nobuyuki Matsuhashi, Mineo Kudo, Norimasa Yoshida, Kazunari Murakami, Mototsugu Kato, Tsuyoshi Sanuki, Atsushi Oshio, Takashi Joh, Kazuhide Higuchi, Ken Haruma, Koji Nakada

Published in: Journal of Gastroenterology | Issue 12/2015

Login to get access

Abstract

Background

Proton pump inhibitor (PPI) therapy, the first-line treatment for gastroesophageal reflux disease (GERD), is not always effective. This study aimed to examine the effect of pretreatment patient characteristics on response to PPI therapy.

Methods

Japanese outpatients with symptomatic GERD scheduled to receive endoscopy and PPI therapy were enrolled in this multicenter prospective observational study. The patients’ characteristics, including GERD and dyspeptic symptoms, anxiety, depression, and quality of life, were assessed using questionnaires before and 2 and 4 weeks after the start of PPI therapy. Factors affecting therapeutic response were examined by simple and multiple regression analyses using three patient-reported outcome measures as objective variables.

Results

Data from 182 patients were analyzed. In multiple regression analysis using the residual symptom rate as an objective variable, lower GERD symptom score (p < 0.05), absence of erosive esophagitis (p < 0.05), higher epigastric pain/burning symptom score (p < 0.05), and higher depression subscale score (p < 0.05) accompanied poorer therapeutic response. In analyses using the patient’s impression of therapy, lower GERD symptom score (p < 0.05) and absence of erosive esophagitis (p < 0.05) accompanied poorer therapeutic response. In analyses using the relative GERD symptom intensity evaluated using a numeric rating scale, lower GERD symptom score (p < 0.05), higher epigastric pain/burning symptom score (p < 0.1), and lower body mass index (p < 0.05) accompanied poorer therapeutic response.

Conclusions

Patients who complained of milder GERD symptoms before treatment were likely to have poorer response to PPI therapy. Association of absence of erosive esophagitis, severer epigastric pain/burning symptoms, lower body mass index, and severer depression with poorer therapeutic response was also suggested.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.CrossRefPubMed Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.CrossRefPubMed
2.
go back to reference Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205–8.CrossRefPubMed Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet. 1990;335:205–8.CrossRefPubMed
3.
go back to reference Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.CrossRefPubMed Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.CrossRefPubMed
4.
go back to reference Mearin F, Ponce J, Ponce M, et al. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2012;24:665–74.CrossRefPubMed Mearin F, Ponce J, Ponce M, et al. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2012;24:665–74.CrossRefPubMed
5.
go back to reference Oh JH, Kim TS, Choi MG, et al. Relationship between psychological factors and quality of life in subtypes of gastroesophageal reflux disease. Gut Liver. 2009;3:259–65.PubMedCentralCrossRefPubMed Oh JH, Kim TS, Choi MG, et al. Relationship between psychological factors and quality of life in subtypes of gastroesophageal reflux disease. Gut Liver. 2009;3:259–65.PubMedCentralCrossRefPubMed
6.
go back to reference Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98:S31–9.CrossRefPubMed Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98:S31–9.CrossRefPubMed
7.
go back to reference The Japanese Society of Gastroenterology. GERD management guideline. Tokyo: Nankodo; 2009. The Japanese Society of Gastroenterology. GERD management guideline. Tokyo: Nankodo; 2009.
8.
go back to reference Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.CrossRefPubMed Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.CrossRefPubMed
9.
go back to reference Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.CrossRefPubMed Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.CrossRefPubMed
10.
go back to reference Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–6.CrossRefPubMed Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–6.CrossRefPubMed
11.
go back to reference Heading RC, Mönnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol. 2011;11:52.PubMedCentralCrossRefPubMed Heading RC, Mönnikes H, Tholen A, et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol. 2011;11:52.PubMedCentralCrossRefPubMed
12.
go back to reference Niu XP, Yu BP, Wang YD, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol. 2013;19:3124–9.PubMedCentralCrossRefPubMed Niu XP, Yu BP, Wang YD, et al. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease. World J Gastroenterol. 2013;19:3124–9.PubMedCentralCrossRefPubMed
13.
go back to reference Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–83.CrossRefPubMed Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–83.CrossRefPubMed
14.
go back to reference Ang D, Talley NJ, Simren M, et al. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther. 2011;33:634–49.CrossRefPubMed Ang D, Talley NJ, Simren M, et al. Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther. 2011;33:634–49.CrossRefPubMed
16.
go back to reference Hoshihara Y. GERD-gastroesophageal reflux disease. Endoscopic diagnosis and classification. Rinshou Shoukakinaika. 1996;11:1563–8. Hoshihara Y. GERD-gastroesophageal reflux disease. Endoscopic diagnosis and classification. Rinshou Shoukakinaika. 1996;11:1563–8.
17.
go back to reference Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41:95–9.CrossRefPubMed Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41:95–9.CrossRefPubMed
18.
go back to reference Nakada K, Joh T, Higuchi K, et al. What factors determine whether a gastroesophageal reflux disease (GERD) patient is responder or not to proton pump inhibitor (PPI) therapy? Gastroenterology. 2013;144(Suppl 1):S-856.CrossRef Nakada K, Joh T, Higuchi K, et al. What factors determine whether a gastroesophageal reflux disease (GERD) patient is responder or not to proton pump inhibitor (PPI) therapy? Gastroenterology. 2013;144(Suppl 1):S-856.CrossRef
19.
go back to reference Nakada K, Joh T, Higuchi K, et al. Symptoms of functional dyspepsia rather than those of gastroesophageal reflux disease decrease the health-related quality of life of patients. Gastroenterology. 2013;144(Suppl 1):S-683.CrossRef Nakada K, Joh T, Higuchi K, et al. Symptoms of functional dyspepsia rather than those of gastroesophageal reflux disease decrease the health-related quality of life of patients. Gastroenterology. 2013;144(Suppl 1):S-683.CrossRef
20.
go back to reference Fukuhara S, Suzukamo Y. Manual of the SF-8 Japanese version. Tokyo: Institute for Health Outcomes and Process Evaluation Research; 2004. Fukuhara S, Suzukamo Y. Manual of the SF-8 Japanese version. Tokyo: Institute for Health Outcomes and Process Evaluation Research; 2004.
21.
go back to reference Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
23.
go back to reference Whitehead WE, Palsson OS, Levy RL, et al. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol. 2006;101:1057–65.CrossRefPubMed Whitehead WE, Palsson OS, Levy RL, et al. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol. 2006;101:1057–65.CrossRefPubMed
24.
go back to reference Spiegel B, Camilleri M, Bolus R, et al. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology. 2009;137:1944–53.PubMedCentralCrossRefPubMed Spiegel B, Camilleri M, Bolus R, et al. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. Gastroenterology. 2009;137:1944–53.PubMedCentralCrossRefPubMed
25.
go back to reference Passos MC, Lembo AJ, Conboy LA, et al. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009;104:912–9.PubMedCentralCrossRefPubMed Passos MC, Lembo AJ, Conboy LA, et al. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009;104:912–9.PubMedCentralCrossRefPubMed
26.
go back to reference Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49:1469–76.CrossRefPubMed Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49:1469–76.CrossRefPubMed
28.
go back to reference Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group. Digestion. 2009;80:74–88.PubMedCentralCrossRefPubMed Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease—the Vevey NERD Consensus Group. Digestion. 2009;80:74–88.PubMedCentralCrossRefPubMed
29.
go back to reference Wu JC, Lai LH, Chow DK, et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastroesophageal reflux disease. Neurogastroenterol Motil. 2011;23:155–60.CrossRefPubMed Wu JC, Lai LH, Chow DK, et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastroesophageal reflux disease. Neurogastroenterol Motil. 2011;23:155–60.CrossRefPubMed
Metadata
Title
Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study
Authors
Nobuyuki Matsuhashi
Mineo Kudo
Norimasa Yoshida
Kazunari Murakami
Mototsugu Kato
Tsuyoshi Sanuki
Atsushi Oshio
Takashi Joh
Kazuhide Higuchi
Ken Haruma
Koji Nakada
Publication date
01-12-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 12/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1073-0

Other articles of this Issue 12/2015

Journal of Gastroenterology 12/2015 Go to the issue